UK approves revolutionary new allergy spray

In a historic development, the United Kingdom became one of first countries in world to approve an adrenaline nasal spray that can be used as an emergency treatment for anaphylaxis. The Medicines and Healthcare products Regulatory Agency, (MHRA), announced on 18 July 2025 that EURneffy was approved. This marks a significant advancement in the management and treatment of severe allergies.

This approval offers an alternative to auto-injectors like EpiPens, which are traditionally used for adrenaline injections. EURneffy delivers adrenaline in a rapid and easy-to-use nasal spray.

Urgent Medical Care

Anaphylaxis (a life-threatening reaction) can occur minutes after being exposed to allergens. These include foods, insect stings and certain medications. The symptoms can become more severe, leading to breathing problems, swelling, blood pressure drops, and even death if untreated.

Auto-injectors for adrenaline were the standard emergency treatment until recently. Many patients have reported anxiety about needles, hesitation to administer the injection or practical problems such as carrying bulky equipment. EURneffy attempts to overcome these barriers through a rapid delivery of adrenaline 2mg via the nasal cavity. It makes treatment more simple and acceptable, particularly for children or those with needle phobia. EURneffy was approved after extensive clinical tests demonstrating its effectiveness and safety. The nasal spray works through absorbing adrenaline in the rich blood vessels within the nose. It provides a quick response comparable to auto injectors. According to the MHRA, the product has shown consistent performance, including in cases where individuals may have nasal congestion—a common concern for patients using nasal medications.

The authorisation covers adults and children that weigh at least 30 kilograms (66 pounds). If allergic symptoms persist even after the first dose of EURneffy, a second dose is recommended following the standard anaphylaxis protocol.

International Recognition Procedure

The approval was given under the MHRA International Recognition Procedure. This allows quicker access to certain medical devices in the UK, by recognising prior authorisations from trusted international jurisdictions. The UK now aligns itself with other countries that have recently approved the product, such as parts of the European Union and the United States. Julian Beach said that the MHRA has a role to play in ensuring medicines are effective and safe. EURneffy is the first nasal spray with adrenaline that does not require needles. We approved it after a thorough review of its quality, safety, and efficacy. The risk of anaphylaxis is high for those who carry and are trained to use adrenaline.

To Better Allergy Care In The UK

EURneffy has been welcomed by healthcare professionals and patient advocacy organizations, who have highlighted its potential to reduce treatment barriers during emergencies. Most allergy patients, especially children and young adults express a reluctance in carrying or using adrenaline auto-injectors because of fear of needles or stigma or the inconveniences of transporting injection device. The nasal spray is small, discrete, and easy-to-use. This is expected to increase compliance and response rates when anaphylactic reactions occur. The nasal spray has a shelflife that is comparable to injectors. Therefore, it can be used for long-term emergency preparedness. ALK-Abelló A/S, the company behind EURneffy, has announced plans to commercialise the nasal spray in the UK by late summer 2025. The company specializes in allergy treatment and expects that the product will become an essential tool for emergency allergy management. The approval of EURneffy coincides with a growing demand for better allergy care in UK. Recent studies show that severe food allergy cases are on the rise, especially among young children. The tragic deaths that occurred when individuals were unable to receive timely adrenaline treatments have highlighted the importance of quick and user-friendly emergency intervention.

Patient safety charities have welcomed the approval. EURneffy is a non-invasive, quick way to administer vital medication in an emergency. British Society for Allergy and Clinical Immunology, (BSACI), has said that nasal options are a welcome addition. While adrenaline injections will still be essential in emergency situations, the British Society for Allergy and Clinical Immunology believes that having a nasal solution is an important option. EURneffy is now available in the UK. This represents a major step in providing allergy sufferers, caregivers, and healthcare professionals with more flexible treatment options.